FDA on Wednesday outlined a proposal that would help reduce the use of some antibiotics in animal production to counter bacterial resistance to those drugs when they are prescribed for humans. *It appears FDA aims to halt or curtail the use of antibiotics for weight gain, Chicago- based Daniels Trading commodities broker Craig Turner told Reuters.» Read More
NEW YORK-- Immunomedics said Wednesday its cancer drug IMMU-132 will receive orphan drug incentives as a treatment for small cell lung cancer. Shares of Immunomedics rose 42 cents, or 9.5 percent, to $4.84 in midday trading. Immunomedics Inc. has no approved drugs.
NEW YORK-- Shares of Ambit Biosciences tumbled Wednesday after the company said it won't file for accelerated approval of its leukemia drug quizartinib, and will run a late-stage clinical trial instead. The company has been meeting with the Food and Drug Administration to discuss quizartinib, a potential treatment for acute myeloid leukemia.
WESTMINSTER, Colo.-- Federal regulators gave the go-ahead to Arca Biopharma to begin human clinical testing of its treatment for atrial fibrillation, the company said Wednesday. Arca believes it has identified genetic variations that predict whether a patient will be helped by treatment with the drug Gencaro.
Shares of ChemoCentryx Inc. advanced Wednesday before markets opened and a day after the drug developer said it was encouraged by initial results from a mid-stage study of a potential autoimmune disease treatment.
Dec 4- Oculus Innovative Sciences Inc's shares more than doubled after the U.S. Food and Drug Administration approved the company's anti-scar treatment for raised and red scars resulting from burns, surgical procedures and trauma wounds. This is the eighth FDA approval for Microcyn-based products, Oculus CEO Jim Schutz said in a statement on Wednesday.
NEW YORK-- Shares of medical device maker Unilife rose Tuesday after the company said it signed a supply deal with Swiss drugmaker Novartis. Unilife said it will supply Novartis with a customized drug delivery device that will allow the Novartis drug to be delivered to a targeted organ.
NEW YORK, Dec 3- A U.S. federal judge has awarded AstraZeneca Plc $76 million in damages from generic drug manufacturer Apotex for infringing upon patents for AstraZeneca's blockbuster heartburn drug, Prilosec, between 2003 and 2007..
NEW YORK, Dec 3- Ben Venue Laboratories, a Bedford, Ohio- based subsidiary of German drugmaker Boehringer Ingelheim has tapped Bank of America Merrill Lynch to explore a possible sale of its generic sterile injectable drugs business.
FRANKFURT, Dec 3- Swiss drugmaker Novartis is ready to sell its animal health subsidiary and has opened its books to Bayer and other rivals interested in a business that could change hands for more than 3 billion euros, sources familiar with the matter told Reuters.
*Celgene to take 5 pct stake in OncoMed. *Celgene stock down 1.4 pct. Dec 3- Shares of OncoMed Pharmaceuticals Inc more than doubled on Tuesday after the biotechnology company said Celgene Corp would help it develop and market six of its experimental anti-cancer stem cell drugs.
Shares of OncoMed Pharmaceuticals Inc. soared Tuesday after the cancer treatment developer announced an agreement with specialty drugmaker Celgene Corp. that could wind up being worth more than $1 billion.
*Copies of antibody drugs start to hit market in Europe. *Norway plans studies to reassure on safety of switching. But although Europe has pioneered their path to market- approving the first biosimilar drug in 2006 and the latest, an antibody drug from U.S.-based Hospira and Celltrion of South Korea, in September- uptake has been patchy.
Nov 29- Atrium Innovations Inc said a group of investors, including European private equity firm Permira funds, would buy the dietary supplements maker for about C $751.2 million. Atrium shareholders will receive C $24 in cash per share, a nearly 23 percent premium to the stock's Thursday close on the Toronto Stock Exchange.
Nov 27- Researchers have found a higher rate of dangerous blood clots in patients who received Thoratec Corp's HeartMate II heart pump than had been seen in clinical trials or prior experience, according to a study published on Wednesday. The findings were reported in the New England Journal of Medicine.
Nov 27- Researchers have found a higher rate of dangerous blood clots forming in patients who received Thoratec Corp's HeartMate II heart pump than had been seen in clinical trials or prior experience, according to a study published on Wednesday.
Nov 27- CVS Caremark Corp will buy drug infusion services provider Coram LLC for $2.1 billion, allowing the company to bolster its pharmacy benefits management business by offering cost-effective delivery of specialty drugs.
Nov 27- CVS Caremark Corp said on Wednesday it was buying Coram LLC, Apria Healthcare Group Inc's specialty infusion services and enteral nutrition business unit, for $2.1 billion.
NEW DELHI, Nov 26- India's finance ministry is resisting pressure from other departments to cap foreign ownership of domestic drugmakers, fearing such a move would discourage potential investors, a senior ministry source said.
An "import alert" results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices, according to the FDA website.
YAVNE, Israel, Nov 26- German healthcare group Merck KGaA is looking for acquisitions and collaborations with start-ups to grow its drugs business in the United States, a senior Merck official said.